Twenty Years of Ferroportin Disease: A Review or An Update of Published Clinical, Biochemical, Molecular, and Functional Features
Open accessThe DOI matches its Crossref record; 151 of the 151 references it cites were found in a registry or an index.
Abstract
Iron overloading disorders linked to mutations in ferroportin have diverse phenotypes in vivo, and the effects of mutations on ferroportin in vitro range from loss of function (LOF) to gain of function (GOF) with hepcidin resistance. We reviewed 359 patients with 60 ferroportin variants. Overall, macrophage iron overload and low/normal transferrin saturation (TSAT) segregated with mutations that caused LOF, while GOF mutations were linked to high TSAT and parenchymal iron accumulation. However, the pathogenicity of individual variants is difficult to establish due to the lack of sufficiently reported data, large inter-assay variability of functional studies, and the uncertainty associated with the performance of available in silico prediction models. Since the phenotypes of hepcidin-resistant GOF variants are indistinguishable from the other types of hereditary hemochromatosis (HH), these variants may be categorized as ferroportin-associated HH, while the entity ferroportin disease may be confined to patients with LOF variants. To further improve the management of ferroportin disease, we advocate for a global registry, with standardized clinical analysis and validation of the functional tests preferably performed in human-derived enterocytic and macrophagic cell lines. Moreover, studies are warranted to unravel the definite structure of ferroportin and the indispensable residues that are essential for functionality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 The two-dimensional (2D) structure of ferroportin protein adapted from Liu and Wallace [6,56], revealing 12 transmembrane helices and six extracellular and five intracellular segments. All the variants described in this review are shown as hepcidin-resistant (pink), hepcidin-sensitive or neutral (purple) and hepcidin conflicting/uncertain/unknown (red) GOF variants (squares). and hepcidin resistant (light blue), hepcidin sensitive (dark blue), and hepcidin conflicting-uncertain-unknown (green) LOF variants (dots), or non-classified variants (grey asterix).](https://figures.cochat.ai/paper-figures/372b17ce55994870988faf6b6062f0f6/twenty-years-of-ferroportin-disease-a-review-or-an-update-of-published-clinical-figure-3.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A confluence of human genetics studies and structure-function evaluations have identified key regions of FPN important in hepcidin regulation 7,19-22 .”
From Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms (2020) · cites this paper as [19]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutation of several residues within the intracellular gate leads to FPN loss of function in ferroportin disease, highlighting the importance of the gate in coordinating the conformational steps necessary for iron efflux 19,28 .”
From Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms (2020) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594 · cited 2×
“To assess co-segregation in multiple affected family members, the simplified method of segregation analysis (SISA) was applied [22,23] and classified according to recent recommendations to define co-segregation to fit the guidelines of the American College of Medical Genetics and Genomics and the Association for Molec…”
MethodHepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803 · cited 2×
“Ferroportin is expressed on the enterocytic basolateral membrane and predominantly in intramacrophagic vesicles [108,131], and there are indications that the mode of hepcidin-induced internalization differs in macrophages [120,132].”
WHAT IF: A molecular modeling and drug design program
Vriend, G. (1990) · Journal of Molecular Graphics · doi:10.1016/0263-7855(90)80070-v · Cited by 3,469 · cited 3×
“For the two-dimensional (2D) model (Figure 3), we adapted the structure constructed by Liu and Wallace [6,56] and for three-dimensional (3D) model (Figure 4), we used Pharmaceuticals 2019, 12, 132 17 of 29 the recently developed model (Bacterial ferroportin, PDB file 5AYN) and homology modeling in the Yet Another Scie…”
MethodPositional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter
Donovan, A., Brownlie, A., Zhou, Y., Shepard, J., Pratt, S. J., Moynihan, J., Paw, B. H., Drejer, A., Barut, B., Zapata, A., et al. (2000) · Nature · doi:10.1038/35001596 · Cited by 1,667
Increasing the precision of comparative models with YASARA NOVA—a self‐parameterizing force field
Krieger, E., Koraimann, G., & Vriend, G. (2002) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.10104 · Cited by 1,514 · cited 3×
“For the two-dimensional (2D) model (Figure 3), we adapted the structure constructed by Liu and Wallace [6,56] and for three-dimensional (3D) model (Figure 4), we used Pharmaceuticals 2019, 12, 132 17 of 29 the recently developed model (Bacterial ferroportin, PDB file 5AYN) and homology modeling in the Yet Another Scie…”
MethodMcKie, A. T., Marciani, P., Rolfs, A., Brennan, K., Wehr, K., Barrow, D., Miret, S., Bomford, A., Peters, T. J., Farzaneh, F., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80425-6 · Cited by 1,422
The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis
Donovan, A., Lima, C. A., Pinkus, J. L., Pinkus, G. S., Zon, L. I., Robine, S., & Andrews, N. C. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.01.003 · Cited by 1,275
A Novel Mammalian Iron-regulated Protein Involved in Intracellular Iron Metabolism
Abboud, S., & Haile, D. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000713200 · Cited by 1,267 · cited 1×
“Ferroportin is expressed on the enterocytic basolateral membrane and predominantly in intramacrophagic vesicles [108,131], and there are indications that the mode of hepcidin-induced internalization differs in macrophages [120,132].”
BackgroundSerum ferritin: Past, present and future
Wang, W., Knovich, M. A., Coffman, L. G., Torti, F. M., & Torti, S. V. (2010) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2010.03.011 · Cited by 879 · cited 1×
“This corroborates the notion that high TSAT facilitates parenchymal iron deposition, which is considered to be more toxic than macrophage iron overload [154].”
BackgroundMuckenthaler, M. U., Galy, B., & Hentze, M. W. (2008) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.28.061807.155521 · Cited by 701
Drakesmith, H., Nemeth, E., & Ganz, T. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.09.006 · Cited by 638 · cited 2×
“In the most widely accepted secondary structure, ferroportin comprises 12 helices located in 12 transmembrane (TM) domains bound via six extracellular (ES) and five intracellular (IS) segments with a large intracellular loop between the sixth and seventh transmembrane helix and intracellularly located N and C terminus…”
BackgroundSelf-citationOrchestration of Metabolism by Macrophages
Biswas, S. K., & Mantovani, A. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2011.11.013 · Cited by 586
Autosomal-dominant hemochrom-atosis is associated with a mutation in the ferroportin (SLC11A3) gene
Montosi, G., Donovan, A., Totaro, A., Garuti, C., Pignatti, E., Cassanelli, S., Trenor, C. C., Gasparini, P., Andrews, N. C., & Pietrangelo, A. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13468 · Cited by 561 · cited 1×
“In contrast to the current consensus [1,2,4,6,8,40,71,83,92,105], patients with LOF variants were not less tolerant to phlebotomy than patients with GOF variants (Table 3).”
ResultAutosomal-dominant hemochrom-atosis is associated with a mutation in the ferroportin (SLC11A3) gene
Montosi, G., Donovan, A., Totaro, A., Garuti, C., Pignatti, E., Cassanelli, S., Trenor, C. C., Gasparini, P., Andrews, N. C., & Pietrangelo, A. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200113468 · Cited by 557
A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis
Njajou, O. T., Vaessen, N., Joosse, M., Berghuis, B., van Dongen, J. W. F., Breuning, M. H., Snijders, P. J. L. M., Rutten, W. P. F., Sandkuijl, L. A., Oostra, B. A., et al. (2001) · Nature Genetics · doi:10.1038/90038 · Cited by 492
Hepcidin in iron overload disorders
Papanikolaou, G., Tzilianos, M., Christakis, J. I., Bogdanos, D., Tsimirika, K., MacFarlane, J., Goldberg, Y. P., Sakellaropoulos, N., Ganz, T., & Nemeth, E. (2005) · Blood · doi:10.1182/blood-2004-12-4844 · Cited by 445
Theurl, I., Aigner, E., Theurl, M., Nairz, M., Seifert, M., Schroll, A., Sonnweber, T., Eberwein, L., Witcher, D. R., Murphy, A. T., et al. (2009) · Blood · doi:10.1182/blood-2008-12-195651 · Cited by 421
Pietrangelo, A. (2004) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2003.08.003 · Cited by 383 · cited 2×
“In contrast to the current consensus [1,2,4,6,8,40,71,83,92,105], patients with LOF variants were not less tolerant to phlebotomy than patients with GOF variants (Table 3).”
ResultFerroportin-mediated iron transport: Expression and regulation
Ward, D. M., & Kaplan, J. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.03.004 · Cited by 373 · cited 2×
“Residues found to be involved in internalization include Tyr64, Gly80, andAsn144, and the residues Lys229, Lys253, and Lys269 are present in the large intracellular loop, and seem to be involved in the degradation of ferroportin [39,114,122].”
BackgroundThe IRP/IRE system in vivo: insights from mouse models
Wilkinson, N., & Pantopoulos, K. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00176 · Cited by 366
Hepcidin-Induced Endocytosis of Ferroportin Is Dependent on Ferroportin Ubiquitination
Qiao, B., Sugianto, P., Fung, E., del-Castillo-Rueda, A., Moran-Jimenez, M.-J., Ganz, T., & Nemeth, E. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.03.018 · Cited by 334 · cited 1×
“Residues found to be involved in internalization include Tyr64, Gly80, andAsn144, and the residues Lys229, Lys253, and Lys269 are present in the large intracellular loop, and seem to be involved in the degradation of ferroportin [39,114,122].”
BackgroundAschemeyer, S., Qiao, B., Stefanova, D., Valore, E. V., Sek, A. C., Ruwe, T. A., Vieth, K. R., Jung, G., Casu, C., Rivella, S., et al. (2018) · Blood · doi:10.1182/blood-2017-05-786590 · Cited by 325 · cited 7×
“Cys326Tyr PM = no no ↓/no uptake 4 4 [8,31,34,35,39–44] Tyr333His PM = no no 5 5 [45] Tyr501Cys PM = no no ↓binding 7 2 5 [30,33,46] Asp504Asn PM = no no ↓binding/uptake 2 2 [8,30] His507Arg PM = no no ↓↓ubiquitination 4 4 [30,41,47]”
BackgroundInfluentialMembrane-bound serine protease matriptase-2 (Tmprss6) is an essential regulator of iron homeostasis
Folgueras, A. R., de Lara, F. M., Pendás, A. M., Garabaya, C., Rodríguez, F., Astudillo, A., Bernal, T., Cabanillas, R., López-Otín, C., & Velasco, G. (2008) · Blood · doi:10.1182/blood-2008-04-149773 · Cited by 305
The physiological functions of iron regulatory proteins in iron homeostasis - an update
Zhang, D.-L., Ghosh, M. C., & Rouault, T. A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00124 · Cited by 301
Delaby, C., Pilard, N., Gonçalves, A. S., Beaumont, C., & Canonne-Hergaux, F. (2005) · Blood · doi:10.1182/blood-2005-06-2398 · Cited by 283
Zhang, D.-L., Hughes, R. M., Ollivierre-Wilson, H., Ghosh, M. C., & Rouault, T. A. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.03.006 · Cited by 281
Consideration of Cosegregation in the Pathogenicity Classification of Genomic Variants
Jarvik, G. P., & Browning, B. L. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.04.003 · Cited by 269 · cited 2×
“To assess co-segregation in multiple affected family members, the simplified method of segregation analysis (SISA) was applied [22,23] and classified according to recent recommendations to define co-segregation to fit the guidelines of the American College of Medical Genetics and Genomics and the Association for Molec…”
MethodTaylor, M., Qu, A., Anderson, E. R., Matsubara, T., Martin, A., Gonzalez, F. J., & Shah, Y. M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.03.007 · Cited by 265
Hereditary Hemochromatosis in Adults without Pathogenic Mutations in the Hemochromatosis Gene
Pietrangelo, A., Montosi, G., Totaro, A., Garuti, C., Conte, D., Cassanelli, S., Fraquelli, M., Sardini, C., Vasta, F., & Gasparini, P. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411003 · Cited by 265 · cited 1×
“In contrast to the current consensus [1,2,4,6,8,40,71,83,92,105], patients with LOF variants were not less tolerant to phlebotomy than patients with GOF variants (Table 3).”
ResultResistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin
Drakesmith, H., Schimanski, L. M., Ormerod, E., Merryweather-Clarke, A. T., Viprakasit, V., Edwards, J. P., Sweetland, E., Bastin, J. M., Cowley, D., Chinthammitr, Y., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0561 · Cited by 264 · cited 6×
“The membrane expression of variant ferroportin proteins was determined by surface biotinylation and Western blotting [8,39], immunofluorescence [6,31–33,40,42,46,55–57,65,87] and confocal microscopy [11,34,41,83], or flow cytometry [31,35,41,42,56].”
BackgroundMethodResultInfluentialSelf-citationThe molecular basis of ferroportin-linked hemochromatosis
De Domenico, I., Ward, D. M., Nemeth, E., Vaughn, M. B., Musci, G., Ganz, T., & Kaplan, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503804102 · Cited by 230
In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations
Schimanski, L. M., Drakesmith, H., Merryweather-Clarke, A. T., Viprakasit, V., Edwards, J. P., Sweetland, E., Bastin, J. M., Cowley, D., Chinthammitr, Y., Robson, K. J. H., et al. (2005) · Blood · doi:10.1182/blood-2004-11-4502 · Cited by 212 · cited 5×
“Ala77Asp IC/PM ↓ conflicting not reliable@ no uptake 26 15 11 [1,2,8,11,34,35,39,41,42,56,57, 66,71,73,87–90] Gly80Ser ↓PM ↓& not reliable@ not reliable@ normal uptake& 24 15 3 [8,57,73,87,88,91,92] Ile152Phe PM ↓ ↓ ↓ – 2 [39,93] Asp157Gly IC/PM ↓ conflicting no& – 4 3 1 [8,34,55,56,61] Asp157Tyr ↓PM ↓ – – – 2 1 1 [8,…”
MethodInfluentialSelf-citationDevalia, V., Carter, K., Walker, A. P., Perkins, S. J., Worwood, M., May, A., & Dooley, J. S. (2002) · Blood · doi:10.1182/blood-2001-11-0132 · Cited by 189
The role of the iron responsive element in the control of ferroportin1/IREG1/MTP1 gene expression
Lymboussaki, A., Pignatti, E., Montosi, G., Garuti, C., Haile, D. J., & Pietrangelo, A. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00408-2 · Cited by 178
Hepcidin inhibits apical iron uptake in intestinal cells
Mena, N. P., Esparza, A., Tapia, V., Valdés, P., & Núñez, M. T. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00122.2007 · Cited by 175
Novel mutation in ferroportin1 is associated with autosomal dominant hemochromatosis
Wallace, D. F., Pedersen, P., Dixon, J. L., Stephenson, P., Searle, J. W., Powell, L. W., & Subramaniam, V. N. (2002) · Blood · doi:10.1182/blood.v100.2.692 · Cited by 174
Iron refractory iron deficiency anemia
De Falco, L., Sanchez, M., Silvestri, L., Kannengiesser, C., Muckenthaler, M. U., Iolascon, A., Gouya, L., Camaschella, C., & Beaumont, C. (2013) · Haematologica · doi:10.3324/haematol.2012.075515 · Cited by 174
A novel inflammatory pathway mediating rapid hepcidin-independent hypoferremia
Guida, C., Altamura, S., Klein, F. A., Galy, B., Boutros, M., Ulmer, A. J., Hentze, M. W., & Muckenthaler, M. U. (2015) · Blood · doi:10.1182/blood-2014-08-595256 · Cited by 173
The molecular basis of hepcidin-resistant hereditary hemochromatosis
Fernandes, A., Preza, G. C., Phung, Y., De Domenico, I., Kaplan, J., Ganz, T., & Nemeth, E. (2009) · Blood · doi:10.1182/blood-2008-03-146134 · Cited by 167 · cited 5×
“Cys326Ser PM = no no ↓binding/no uptake 7 6 [30,32,34,37,38]”
BackgroundMethodInfluentialFunctional consequences of ferroportin 1 mutations
Liu, X.-B., Yang, F., & Haile, D. J. (2005) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2005.04.005 · Cited by 156 · cited 4×
“Sum: 7 GOF Hepcidin Sensitive: Neutral 12 7 3 Ala69Thr PM = – ↓! – 4 2 2 [42,51,52] Val72Phe PM = yes ↓! ↓binding 5 2 3 [30,53] Asn144Asp PM =# conflicting no# ↓binding/uptake 2 1 [30–32,35,54] Asn144His PM = conflicting yes ↓uptake 20 13 7 [3,6,31,34,35,39,40,42,55–59] Asn144Thr PM = conflicting yes# ↓uptake 1 1 [6,3…”
InfluentialInhibition of iron transport across human intestinal epithelial cells by hepcidin
Yamaji, S., Sharp, P., Ramesh, B., & Srai, S. K. (2004) · Blood · doi:10.1182/blood-2004-03-0829 · Cited by 152
Ferroportin disease: pathogenesis, diagnosis and treatment
Pietrangelo, A. (2017) · Haematologica · doi:10.3324/haematol.2017.170720 · Cited by 151 · cited 2×
“Since iron distribution patterns and clinical features of patients with hepcidin-resistant GOF variants are indistinguishable from patients with other types of HH, we support the proposition to categorize these variants as ferroportin-associated HH, and to confine the entity ferroportin disease to patients with LOF va…”
BackgroundDomenico, I. D., Lo, E., Ward, D. M., & Kaplan, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900453106 · Cited by 147
Sham, R. L., Phatak, P. D., West, C., Lee, P., Andrews, C., & Beutler, E. (2005) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2004.12.002 · Cited by 146 · cited 1×
“Cys326Ser PM = no no ↓binding/no uptake 7 6 [30,32,34,37,38]”
BackgroundRoss, S. L., Tran, L., Winters, A., Lee, K.-J., Plewa, C., Foltz, I., King, C., Miranda, L. P., Allen, J., Beckman, H., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.03.017 · Cited by 145
Evidence for differential effects of hepcidin in macrophages and intestinal epithelial cells
Chaston, T., Chung, B., Mascarenhas, M., Marks, J., Patel, B., Srai, S. K., & Sharp, P. (2008) · Gut · doi:10.1136/gut.2007.131722 · Cited by 145
Hetet, G., Devaux, I., Soufir, N., Grandchamp, B., & Beaumont, C. (2003) · Blood · doi:10.1182/blood-2003-02-0439 · Cited by 135 · cited 4×
“Sum: 7 GOF Hepcidin Sensitive: Neutral 12 7 3 Ala69Thr PM = – ↓! – 4 2 2 [42,51,52] Val72Phe PM = yes ↓! ↓binding 5 2 3 [30,53] Asn144Asp PM =# conflicting no# ↓binding/uptake 2 1 [30–32,35,54] Asn144His PM = conflicting yes ↓uptake 20 13 7 [3,6,31,34,35,39,40,42,55–59] Asn144Thr PM = conflicting yes# ↓uptake 1 1 [6,3…”
InfluentialFerroportin disease: a systematic meta-analysis of clinical and molecular findings
Mayr, R., Janecke, A. R., Schranz, M., Griffiths, W. J. H., Vogel, W., Pietrangelo, A., & Zoller, H. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.05.016 · Cited by 133 · cited 1×
“In contrast to previous reports [7,105] and the prevailing opinion [10], patients with LOF and GOF variants were found to have a comparable Hb and prevalence of anemia (according to the World Health Organization criteria).”
ResultFerroportin 1 (SCL40A1) variant associated with iron overload in African-Americans
Beutler, E., Barton, J. C., Felitti, V. J., Gelbart, T., West, C., Lee, P. L., Waalen, J., & Vulpe, C. D. (2003) · Blood Cells Molecules and Diseases · doi:10.1016/s1079-9796(03)00165-7 · Cited by 129
Comparative studies of duodenal and macrophage ferroportin proteins
Canonne-Hergaux, F., Donovan, A., Delaby, C., Wang, H.-J., & Gros, P. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00227.2005 · Cited by 124
Taniguchi, R., Kato, H. E., Font, J., Deshpande, C. N., Wada, M., Ito, K., Ishitani, R., Jormakka, M., & Nureki, O. (2015) · Nature Communications · doi:10.1038/ncomms9545 · Cited by 120 · cited 8×
“Extrapolating the experimental model to the human protein reveals that residues Asp84, Arg88, Asp157, Asn174, Gln481, Glu486, and Arg489, which are located at IS1, IS2 and IS5, are important in intracellular gate interaction, while the residues Phe44, Val48, Val 51, Leu58, Asp325, Thr329, Leu342, and Phe520, which are…”
BackgroundInfluentialAltamura, S., Kessler, R., Gröne, H.-J., Gretz, N., Hentze, M. W., Galy, B., & Muckenthaler, M. U. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.07.007 · Cited by 119 · cited 1×
“Observations in mice with the Cys326Ser variant reveal that increased dietary iron absorption is maintained by the upregulation of the Duodenal cytochrome b (Dcytb) and Divalent Metal Transporter 1 (DMT1) at the apical site of the enterocyte, which is likely to compensate for the pending intraenterocytic iron depletio…”
BackgroundRice, A. E., Mendez, M. J., Hokanson, C. A., Rees, D. C., & Björkman, P. J. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.12.063 · Cited by 110 · cited 4×
“Sum: 7 GOF Hepcidin Sensitive: Neutral 12 7 3 Ala69Thr PM = – ↓! – 4 2 2 [42,51,52] Val72Phe PM = yes ↓! ↓binding 5 2 3 [30,53] Asn144Asp PM =# conflicting no# ↓binding/uptake 2 1 [30–32,35,54] Asn144His PM = conflicting yes ↓uptake 20 13 7 [3,6,31,34,35,39,40,42,55–59] Asn144Thr PM = conflicting yes# ↓uptake 1 1 [6,3…”
BackgroundInfluentialCeruloplasmin-ferroportin system of iron traffic in vertebrates
Musci, G. (2014) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v5.i2.204 · Cited by 108
Lee, P. L., Gelbart, T., West, C., Halloran, C., Felitti, V. J., & Beutler, E. (2001) · Blood Cells Molecules and Diseases · doi:10.1006/bcmd.2001.0445 · Cited by 107
Pietrangelo, A., Caleffi, A., & Corradini, E. (2011) · Seminars in Liver Disease · doi:10.1055/s-0031-1286061 · Cited by 107
A valine deletion of ferroportin 1: a common mutation in hemochromatosis type 4?
Roetto, A., Merryweather‐Clarke, A. T., Daraio, F., Livesey, K., Pointon, J. J., Barbabietola, G., Piga, A. G., Mackie, P. H., Robson, K., & Camaschella, C. (2002) · Blood · doi:10.1182/blood-2002-03-0693 · Cited by 103
Iron overload in the Asian community
Lok, C. Y., Merryweather-Clarke, A. T., Viprakasit, V., Chinthammitr, Y., Srichairatanakool, S., Limwongse, C., Oleesky, D., Robins, A. J., Hudson, J., Wai, P., et al. (2009) · Blood · doi:10.1182/blood-2009-01-199109 · Cited by 97
Cazzola, M., Cremonesi, L., Papaioannou, M., Soriani, N., Kioumi, A., Charalambidou, A., Paroni, R. C., Romtsou, K., Levi, S., Ferrari, M., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03946.x · Cited by 96
‘Ride on the ferrous wheel’ – The cycle of iron in macrophages in health and disease
Nairz, M., Schroll, A., Demetz, E., Tancevski, I., Theurl, I., & Weiss, G. (2015) · Immunobiology · doi:10.1016/j.imbio.2014.09.010 · Cited by 89 · cited 1×
“Ferroportin is expressed on the enterocytic basolateral membrane and predominantly in intramacrophagic vesicles [108,131], and there are indications that the mode of hepcidin-induced internalization differs in macrophages [120,132].”
BackgroundRole of Hepcidin in the Setting of Hypoferremia during Acute Inflammation
Deschemin, J.-C., & Vaulont, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061050 · Cited by 89
A novel mutation in ferroportin1 is associated with haemochromatosis in a Solomon Islands patient
Arden, K. E., Wallace, D. F., Dixon, J. L., Summerville, L., Searle, J. W., Anderson, G. J., Ramm, G. A., Powell, L. W., & Subramaniam, V. N. (2003) · Gut · doi:10.1136/gut.52.8.1215 · Cited by 84 · cited 1×
“Sum: 7 GOF Hepcidin Sensitive: Neutral 12 7 3 Ala69Thr PM = – ↓! – 4 2 2 [42,51,52] Val72Phe PM = yes ↓! ↓binding 5 2 3 [30,53] Asn144Asp PM =# conflicting no# ↓binding/uptake 2 1 [30–32,35,54] Asn144His PM = conflicting yes ↓uptake 20 13 7 [3,6,31,34,35,39,40,42,55–59] Asn144Thr PM = conflicting yes# ↓uptake 1 1 [6,3…”
Donker, A. E., Raymakers, R. A. P., Vlasveld, L. T., van Barneveld, T., Terink, R., Dors, N., Brons, P. P. T., Knoers, N. V. A. M., & Swinkels, D. W. (2014) · Blood · doi:10.1182/blood-2014-01-548776 · Cited by 83
Self-citationWallace, D. F., Clark, R. M., Harley, H. A. J., & Subramaniam, V. N. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2003.12.008 · Cited by 83
Novel mutation in ferroportin 1 gene is associated with autosomal dominant iron overload
Jouanolle, A., Douabin-Gicquel, V., Halimi, C., Loréal, O., Fergelot, P., Delacour, T., de Lajarte‐Thirouard, A., Turlin, B., Gall, J. L., Cadet, E., et al. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00148-x · Cited by 82 · cited 1×
“Sum: 13 GOF Uncertain/Conflicting/Unknown 61 32 27 Asp84Glu – ↓ no – – 1 [43] Val162del IC/↓PM ↓ no no ↓↓uptake 50 39 2 [6,8,35,43,51,55,56,66–79] Asp181Asn PM ↓ no no – 6 6 [51] Asp181Val ↓PM ↓ no no – 10 10 [8,42,46,80] Gly490Asp IC/PM ↓ no no no uptake 12 9 3 [8,34,55,81]”
Wallace, D. F., Harris, J. M., & Subramaniam, V. N. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00621.2008 · Cited by 80 · cited 9×
“Sum: 7 GOF Hepcidin Sensitive: Neutral 12 7 3 Ala69Thr PM = – ↓! – 4 2 2 [42,51,52] Val72Phe PM = yes ↓! ↓binding 5 2 3 [30,53] Asn144Asp PM =# conflicting no# ↓binding/uptake 2 1 [30–32,35,54] Asn144His PM = conflicting yes ↓uptake 20 13 7 [3,6,31,34,35,39,40,42,55–59] Asn144Thr PM = conflicting yes# ↓uptake 1 1 [6,3…”
BackgroundMethodResultInfluentialHan, O., & Kim, E. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21392 · Cited by 77 · cited 1×
“After iron egress from enterocytes, ferrous iron is oxidized by membrane-bound hephaestin, co-located with ferroportin, while ferrous iron release from macrophages is oxidized by circulating ceruloplasmin [139,140].”
BackgroundSham, R. L., Phatak, P. D., Nemeth, E., & Ganz, T. (2009) · Blood · doi:10.1182/blood-2009-04-216226 · Cited by 74 · cited 1×
“Cys326Ser PM = no no ↓binding/no uptake 7 6 [30,32,34,37,38]”
BackgroundGenetic and clinical heterogeneity of ferroportin disease
Cemonesi, L., Forni, G. L., Soriani, N., Lamagna, M., Fermo, I., Daraio, F., Galli, A., Pietra, D., Malcovati, L., Ferrari, M., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05815.x · Cited by 71 · cited 4×
“7 Arg88Gly IC/PM ↓ yes --7 3 3 [8,11,82] Leu129Pro PM ↓ yes ↓yes -5 3 2 [83] Arg178Gln PM ↓ yes --26 17 [75,82,84,85] Asn185Asp PM ↓ yes --19 4 6 [9,11,86] Sum: 4 LOF Hepcidin Sensitive 57 27 11 Ala77Asp IC/PM ↓ conflicting not reliable@ no uptake 26 15 11 [1,2,8,11,34,35,39,41,42,56,57,66,71,73,87–90] Gly80Ser ↓PM ↓&…”
InfluentialPrimary iron overload with inappropriate hepcidin expression in V162del ferroportin disease†
Zoller, H., McFarlane, I., Theurl, I., Stadlmann, S., Nemeth, E., Oxley, D., Ganz, T., Halsall, D. J., Cox, T. M., & Vogel, W. (2005) · Hepatology · doi:10.1002/hep.20775 · Cited by 69 · cited 1×
“In contrast, patients heterozygous for LOF variants, which fail to export iron in functional tests, do not develop iron deficiency anemia; instead, they develop systemic, predominantly reticuloendothelial iron overload with limited but consistent proof for iron depletion in the enterocytes [79,88].”
BackgroundSex and Acquired Cofactors Determine Phenotypes of Ferroportin Disease
Lan, C. L., Mosser, A., Ropert, M., Détivaud, L., Loustaud-Ratti, V., Vital-Durand, D., Roget, L. D.-P., Bardou‐Jacquet, E., Turlin, B., David, V., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.12.049 · Cited by 67
Self-citationHereditary hemochromatosis: Mutations in genes involved in iron homeostasis in Brazilian patients
Santos, P. C. J. L., Cançado, R. D., Pereira, A. C., Schettert, I. T., Soares, R. A. G., Pagliusi, R. A., Hirata, R. D. C., Hirata, M. H., Teixeira, A. C., Figueiredo, M. S., et al. (2011) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2011.02.008 · Cited by 65 · cited 2×
“Sum: 7 GOF Hepcidin Sensitive: Neutral 12 7 3 Ala69Thr PM = – ↓! – 4 2 2 [42,51,52] Val72Phe PM = yes ↓! ↓binding 5 2 3 [30,53] Asn144Asp PM =# conflicting no# ↓binding/uptake 2 1 [30–32,35,54] Asn144His PM = conflicting yes ↓uptake 20 13 7 [3,6,31,34,35,39,40,42,55–59] Asn144Thr PM = conflicting yes# ↓uptake 1 1 [6,3…”
BackgroundMayr, R., Griffiths, W. J. H., Hermann, M., McFarlane, I., Halsall, D. J., Finkenstedt, A., Douds, A., Davies, S. E., Janecke, A. R., Vogel, W., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.064 · Cited by 64 · cited 7×
“The membrane expression of variant ferroportin proteins was determined by surface biotinylation and Western blotting [8,39], immunofluorescence [6,31–33,40,42,46,55–57,65,87] and confocal microscopy [11,34,41,83], or flow cytometry [31,35,41,42,56].”
BackgroundMethodInfluentialUnderstanding the Structure/Activity Relationships of the Iron Regulatory Peptide Hepcidin
Clark, R. J., Tan, C. C., Preza, G. C., Nemeth, E., Ganz, T., & Craik, D. J. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.12.009 · Cited by 63 · cited 1×
“Functional studies reveal the internalization of ferroportin upon hepcidin binding with subsequent endosomal and lysosomal degradation resulting in the diminution of cellular iron export, while three-dimensional (3D) structural studies suggest that hepcidin binding disrupts the conformational transition into the intra…”
BackgroundLe Gac, G., Ka, C., Joubrel, R., Gourlaouen, I., Lehn, P., Mornon, J.-P., Férec, C., & Callebaut, I. (2013) · Human Mutation · doi:10.1002/humu.22369 · Cited by 63
Magnetic resonance imaging to identify classic and nonclassic forms of ferroportin disease
Pietrangelo, A., Corradini, E., Ferrara, F., Vegetti, A., Jong, G. D., Abbati, G. L., Arcuri, P. P., Martinelli, S., & Cerofolini, E. (2006) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2006.08.007 · Cited by 63 · cited 3×
“7 Arg88Gly IC/PM ↓ yes --7 3 3 [8,11,82] Leu129Pro PM ↓ yes ↓yes -5 3 2 [83] Arg178Gln PM ↓ yes --26 17 [75,82,84,85] Asn185Asp PM ↓ yes --19 4 6 [9,11,86] Sum: 4 LOF Hepcidin Sensitive 57 27 11 Ala77Asp IC/PM ↓ conflicting not reliable@ no uptake 26 15 11 [1,2,8,11,34,35,39,41,42,56,57,66,71,73,87–90] Gly80Ser ↓PM ↓&…”
Callebaut, I., Joubrel, R., Pissard, S., Kannengiesser, C., Gérolami, V., Ged, C., Cadet, E., Cartault, F., Ka, C., Gourlaouen, I., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu160 · Cited by 63 · cited 4×
“Systematic and narrative reviews on ferroportin disease revealed the great variety in iron parameters among patients with ferroportin variants and emphasize the poor correlation between iron export capacity in functional studies and clinical characteristics (phenotype) [7,9–11] and question the pathogenicity of variou…”
BackgroundInfluentialHuman macrophage ferroportin biology and the basis for the ferroportin disease
Sabelli, M., Montosi, G., Garuti, C., Caleffi, A., Oliveto, S., Biffo, S., & Pietrangelo, A. (2016) · Hepatology · doi:10.1002/hep.29007 · Cited by 60 · cited 1×
“It has been recently suggested that differences in amount of intracellular iron turnover between enterocytes and macrophages may influence iron export capacity of these cells in patients with ferroportin disease due to LOF variants [130].”
Background(2003) · PubMed · Cited by 59
Ferroportin (Q248H) mutations in African families with dietary iron overload
MCNAMARA, L., GORDEUK, V. R., & MACPHAIL, A. P. (2005) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2005.03930.x · Cited by 57
Analysis of genes implicated in iron regulation in individuals presenting with primary iron overload
Zaahl, M. G., Merryweather‐Clarke, A. T., Kotze, M. J., der Merwe, V., Warnich, L., & Robson, K. (2004) · Human Genetics · doi:10.1007/s00439-004-1166-y · Cited by 56
Intestinal expression of genes implicated in iron absorption and their regulation by hepcidin
Bergamaschi, G., Sabatino, A. D., Pasini, A., Ubezio, C., Costanzo, F., Grataroli, D., Masotti, M., Alvisi, C., & Corazza, G. R. (2016) · Clinical Nutrition · doi:10.1016/j.clnu.2016.09.021 · Cited by 56
Ferroportin mutation in autosomal dominant hemochromatosis: loss of function, gain in understanding
Fleming, R. E., & Sly, W. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13739 · Cited by 54
Létocart, É., Gac, G. L., Majore, S., Ka, C., Radio, F. C., Gourlaouen, I., Bernardo, C. D., Férec, C., & Grammatico, P. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07834.x · Cited by 53
Rivers, C. A., Barton, J. C., Gordeuk, V. R., Acton, R. T., Speechley, M. R., Snively, B. M., Leiendecker‐Foster, C., Press, R. D., Adams, P. C., McLaren, G. D., et al. (2007) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2006.12.002 · Cited by 50
Agoro, R., & Mura, C. (2016) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2016.07.006 · Cited by 50
Enculescu, M., Metzendorf, C., Sparla, R., Hahnel, M. J., Bode, J. G., Muckenthaler, M. U., & Legewie, S. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005322 · Cited by 50
Molecular and clinical correlates in iron overload associated with mutations in ferroportin.
Domenico, I. D., Ward, D. M., Nemeth, E., Ganz, T., Corradini, E., Ferrara, F., Musci, G., Pietrangelo, A., & Kaplan, J. (2006) · PubMed · Cited by 49
Dominant Hemochromatosis Due to N144H Mutation of SLC11A3: Clinical and Biological Characteristics
Njajou, O. T., Jong, G. D., Berghuis, B., Vaessen, N., Snijders, P. J. L. M., Jp, G., Wilson, J. H. P., Breuning, M. H., Oostra, B. A., Heutink, P., et al. (2002) · Blood Cells Molecules and Diseases · doi:10.1006/bcmd.2002.0581 · Cited by 48
Ferroportin Diseases: Functional Studies, a Link Between Genetic and Clinical Phenotype
Détivaud, L., Island, M., Jouanolle, A., Ropert, M., Bardou‐Jacquet, E., Lan, C. L., Mosser, A., Leroyer, P., Deugnier, Y., David, V., et al. (2013) · Human Mutation · doi:10.1002/humu.22396 · Cited by 47 · cited 3×
“Sum: 7 GOF Hepcidin Sensitive: Neutral 12 7 3 Ala69Thr PM = – ↓! – 4 2 2 [42,51,52] Val72Phe PM = yes ↓! ↓binding 5 2 3 [30,53] Asn144Asp PM =# conflicting no# ↓binding/uptake 2 1 [30–32,35,54] Asn144His PM = conflicting yes ↓uptake 20 13 7 [3,6,31,34,35,39,40,42,55–59] Asn144Thr PM = conflicting yes# ↓uptake 1 1 [6,3…”
Self-citationFerroportin/IREG-1/MTP-1/SLC40A1 modulates the uptake of iron at the apical membrane of enterocytes
Thomas, C. (2004) · Gut · doi:10.1136/gut.53.1.44 · Cited by 47
Jacolot, S., Férec, C., & Mura, C. (2008) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2008.01.006 · Cited by 46
Girelli, D., Domenico, I. D., Bozzini, C., Campostrini, N., Busti, F., Castagna, A., Soriani, N., Cremonesi, L., Ferrari, M., Colombari, R., et al. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.05.028 · Cited by 45 · cited 3×
“7 Arg88Gly IC/PM ↓ yes --7 3 3 [8,11,82] Leu129Pro PM ↓ yes ↓yes -5 3 2 [83] Arg178Gln PM ↓ yes --26 17 [75,82,84,85] Asn185Asp PM ↓ yes --19 4 6 [9,11,86] Sum: 4 LOF Hepcidin Sensitive 57 27 11 Ala77Asp IC/PM ↓ conflicting not reliable@ no uptake 26 15 11 [1,2,8,11,34,35,39,41,42,56,57,66,71,73,87–90] Gly80Ser ↓PM ↓&…”
Barton, J. C., Delrio-Lafreniere, S. A., Leiendecker‐Foster, C., Li, H., Acton, R. T., Press, R. D., & Eckfeldt, J. H. (2009) · American Journal of Hematology · doi:10.1002/ajh.21524 · Cited by 45
A structural model of human ferroportin and of its iron binding site
Bonaccorsi di Patti, M. C., Polticelli, F., Cece, G., Cutone, A., Felici, F., Persichini, T., & Musci, G. (2014) · The FEBS Journal · doi:10.1111/febs.12825 · Cited by 44
KOYAMA, C., WAKUSAWA, S., HAYASHI, H., UENO, T., SUZUKI, R., YANO, M., SAITO, H., & OKAZAKI, T. (2005) · Internal Medicine · doi:10.2169/internalmedicine.44.990 · Cited by 41
Impaired Iron Transport Activity of Ferroportin 1 in Hereditary Iron Overload
McGregor, J. A., Shayeghi, M., Vulpe, C. D., Anderson, G. J., Pietrangelo, A., Simpson, R. J., & Mckie, A. T. (2005) · Journal of Membrane Biology · doi:10.1007/s00232-005-0768-1 · Cited by 38 · cited 3×
“In most of the transfection studies HEK293T, a human embryonic kidney cell line, was used [6,8,11,31–33,35,39–42,46,55–57,83,87,93] and occasionally Xenophus oocytes, colon carcinoma CaCo-2, or hepatoma HuH7 cell lines [6,57,66].”
BackgroundMethodMutations in the HFE, TFR2, and SLC40A1 genes in patients with hemochromatosis
Rueda, A. D. C., Moreno‐Carralero, M., Cuadrado‐Grande, N., Álvarez-Sala, J. L., de Salamanca, R. E., Méndez, M., & Morán‐Jiménez, M. (2012) · Gene · doi:10.1016/j.gene.2012.07.069 · Cited by 37 · cited 1×
“Sum: 7 GOF Hepcidin Resistant 37 2 34 ILe180Thr PM = yes – normal uptake 3 2 1 [8,48,49] Thr230Asn PM = yes – normal uptake 1 1 [8] Met266Thr PM = yes – normal uptake 1 1 [8] Leu345Phe PM = yes – normal uptake 1 1 [8] Ile351Val PM = yes – ↑uptake 1 1 [8] Pro443Leu PM = yes – ↑uptake 1 [8] Arg561Gly PM = yes – normal u…”
Pelucchi, S., Mariani, R., Salvioni, A., Bonfadini, S., Riva, A., Bertola, F., Trombini, P., & Piperno, A. (2008) · Clinical Genetics · doi:10.1111/j.1399-0004.2007.00950.x · Cited by 37 · cited 4×
“Sum: 7 GOF Hepcidin Sensitive: Neutral 12 7 3 Ala69Thr PM = – ↓! – 4 2 2 [42,51,52] Val72Phe PM = yes ↓! ↓binding 5 2 3 [30,53] Asn144Asp PM =# conflicting no# ↓binding/uptake 2 1 [30–32,35,54] Asn144His PM = conflicting yes ↓uptake 20 13 7 [3,6,31,34,35,39,40,42,55–59] Asn144Thr PM = conflicting yes# ↓uptake 1 1 [6,3…”
InfluentialGlobal Sequencing Approach for Characterizing the Molecular Background of Hereditary Iron Disorders
Cunat, S., Giansily‐Blaizot, M., Bismuth, M., Blanc, F., Dereure, O., Larrey, D. G., Quellec, A. L., Pouderoux, P., Rosé, C., Raingeard, I., et al. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2007.090605 · Cited by 37 · cited 3×
“7 Arg88Gly IC/PM ↓ yes --7 3 3 [8,11,82] Leu129Pro PM ↓ yes ↓yes -5 3 2 [83] Arg178Gln PM ↓ yes --26 17 [75,82,84,85] Asn185Asp PM ↓ yes --19 4 6 [9,11,86] Sum: 4 LOF Hepcidin Sensitive 57 27 11 Ala77Asp IC/PM ↓ conflicting not reliable@ no uptake 26 15 11 [1,2,8,11,34,35,39,41,42,56,57,66,71,73,87–90] Gly80Ser ↓PM ↓&…”
Lack of enterocyte iron accumulation in the ferroportin disease
Corradini, E., Montosi, G., Ferrara, F., Caleffi, A., Pignatti, E., Barelli, S., Garuti, C., & Pietrangelo, A. (2005) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2005.07.010 · Cited by 36 · cited 3×
“7 Arg88Gly IC/PM ↓ yes --7 3 3 [8,11,82] Leu129Pro PM ↓ yes ↓yes -5 3 2 [83] Arg178Gln PM ↓ yes --26 17 [75,82,84,85] Asn185Asp PM ↓ yes --19 4 6 [9,11,86] Sum: 4 LOF Hepcidin Sensitive 57 27 11 Ala77Asp IC/PM ↓ conflicting not reliable@ no uptake 26 15 11 [1,2,8,11,34,35,39,41,42,56,57,66,71,73,87–90] Gly80Ser ↓PM ↓&…”
Reduced sensitivity of the ferroportin Q248H mutant to physiological concentrations of hepcidin
Nekhai, S. A., Xu, M., Foster, A., Kasvosve, I., Diaz, S. F., Machado, R. F., Castro, O. L., Kato, G. J., Taylor, J. G., & Gordeuk, V. R. (2012) · Haematologica · doi:10.3324/haematol.2012.066530 · Cited by 34
Griffiths, W. J. H., Mayr, R., McFarlane, I., Hermann, M., Halsall, D. J., Zoller, H., & Cox, T. M. (2010) · Hepatology · doi:10.1002/hep.23377 · Cited by 33 · cited 6×
“Ala77Asp IC/PM ↓ conflicting not reliable@ no uptake 26 15 11 [1,2,8,11,34,35,39,41,42,56,57, 66,71,73,87–90] Gly80Ser ↓PM ↓& not reliable@ not reliable@ normal uptake& 24 15 3 [8,57,73,87,88,91,92] Ile152Phe PM ↓ ↓ ↓ – 2 [39,93] Asp157Gly IC/PM ↓ conflicting no& – 4 3 1 [8,34,55,56,61] Asp157Tyr ↓PM ↓ – – – 2 1 1 [8,…”
BackgroundMethodResultInfluentialIdentification of ferroportin disease in the Indian subcontinent
Wallace, D. F., Browett, P., Wong, P., Kua, H., Ameratunga, R., & Subramaniam, V. N. (2005) · Gut · doi:10.1136/gut.2004.060988 · Cited by 33
Wang, Y., Du, Y., Liu, G., Guo, S., Hou, B., Jiang, X., Han, B., Chang, Y.-Z., & Nie, G. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2150-8 · Cited by 31 · cited 1×
“Sum: 7 GOF Hepcidin Sensitive: Neutral 12 7 3 Ala69Thr PM = – ↓! – 4 2 2 [42,51,52] Val72Phe PM = yes ↓! ↓binding 5 2 3 [30,53] Asn144Asp PM =# conflicting no# ↓binding/uptake 2 1 [30–32,35,54] Asn144His PM = conflicting yes ↓uptake 20 13 7 [3,6,31,34,35,39,40,42,55–59] Asn144Thr PM = conflicting yes# ↓uptake 1 1 [6,3…”
A novel mutation in ferroportin implicated in iron overload
Wallace, D. F., Dixon, J. L., Ramm, G. A., Anderson, G. J., Powell, L. W., & Subramaniam, V. N. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.01.033 · Cited by 30 · cited 2×
“ubiquitination 1 1 [6,30,65] Arg371Gln IC/PM = no yes – 1 1 [11]”
BackgroundBach, V., Remacha, A. F., Altés, A., Barceló, M. J., Molina, M. A., & Baiget, M. (2005) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2005.09.001 · Cited by 29 · cited 5×
“Sum: 12 LOF Uncertain/Conflicting/Unknown 80 48 21 Tyr64His 1 1 [95] Gly80Val 2 2 [80] Arg88Thr 7 3 4 [48] Asp157Ala 5 2 3 [96–98] Asp157Asn 5 5 [45,53] Ala232Asp 2 2 [99] Lys240Glu 1 1 [100] Gly267Asp 1 1 [80] Cys326Phe 1 1 [101] Gly468Ser 3 3 [102] Arg489Ser 4 2 2 [94,103] Val511Ile 1 1 [45]”
BackgroundInfluentialKa, C., Guellec, J., Pepermans, X., Kannengiesser, C., Ged, C., Wuyts, W. A., Cassiman, D. M., de Lédinghen, V., Varet, B. R., de Kerguenec, C., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.189845 · Cited by 29 · cited 4×
“This interaction may lead to a loss of stabilization of the open-outward conformation that is needed to preserve iron egress [84].”
BackgroundInfluentialZhang, W., Xu, A., Li, Y., Zhao, S., Zhou, D., Wu, L., Zhang, B., Zhao, X., Wang, Y., Wang, X., et al. (2019) · Liver International · doi:10.1111/liv.14013 · Cited by 29
Disease progression and liver cancer in the ferroportin disease
Corradini, E., Ferrara, F., Pollicino, T., Vegetti, A., Abbati, G. L., Losi, L., Raimondo, G., & Pietrangelo, A. (2007) · Gut · doi:10.1136/gut.2007.122549 · Cited by 27 · cited 2×
“Long-term follow-up information and data to determine a difference in clinical course between GOF and LOF variant patients are limited [12,106].”
BackgroundImpact of D181V and A69T on the function of ferroportin as an iron export pump and hepcidin receptor
Praschberger, R., Schranz, M., Griffiths, W. J., Baumgartner, N., Hermann, M., Lomas, D. J., Pietrangelo, A., Cox, T. M., Vogel, W., & Zoller, H. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.05.011 · Cited by 27 · cited 6×
“Sum: 13 GOF Uncertain/Conflicting/Unknown 61 32 27 Asp84Glu – ↓ no – – 1 [43] Val162del IC/↓PM ↓ no no ↓↓uptake 50 39 2 [6,8,35,43,51,55,56,66–79] Asp181Asn PM ↓ no no – 6 6 [51] Asp181Val ↓PM ↓ no no – 10 10 [8,42,46,80] Gly490Asp IC/PM ↓ no no no uptake 12 9 3 [8,34,55,81]”
BackgroundMethodInfluentialClinicopathological study of Japanese patients with genetic iron overload syndromes
Hattori, A., Miyajima, H., Tomosugi, N., Tatsumi, Y., Hayashi, H., & Wakusawa, S. (2012) · Pathology International · doi:10.1111/j.1440-1827.2012.02848.x · Cited by 27 · cited 4×
“7 Arg88Gly IC/PM ↓ yes --7 3 3 [8,11,82] Leu129Pro PM ↓ yes ↓yes -5 3 2 [83] Arg178Gln PM ↓ yes --26 17 [75,82,84,85] Asn185Asp PM ↓ yes --19 4 6 [9,11,86] Sum: 4 LOF Hepcidin Sensitive 57 27 11 Ala77Asp IC/PM ↓ conflicting not reliable@ no uptake 26 15 11 [1,2,8,11,34,35,39,41,42,56,57,66,71,73,87–90] Gly80Ser ↓PM ↓&…”
InfluentialSpeletas, M. G., Kioumi, A., Loules, G., Hytiroglou, P., Tsitouridis, J., Christakis, J. I., & Germenis, A. E. (2007) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2007.09.011 · Cited by 25 · cited 3×
“7 Arg88Gly IC/PM ↓ yes --7 3 3 [8,11,82] Leu129Pro PM ↓ yes ↓yes -5 3 2 [83] Arg178Gln PM ↓ yes --26 17 [75,82,84,85] Asn185Asp PM ↓ yes --19 4 6 [9,11,86] Sum: 4 LOF Hepcidin Sensitive 57 27 11 Ala77Asp IC/PM ↓ conflicting not reliable@ no uptake 26 15 11 [1,2,8,11,34,35,39,41,42,56,57,66,71,73,87–90] Gly80Ser ↓PM ↓&…”
Ferroportin disease due to the A77D mutation in Australia
Subramaniam, V. N. (2005) · Gut · doi:10.1136/gut.2005.069021 · Cited by 25
Møller, P., Clark, N., & Mæhle, L. (2011) · Human Mutation · doi:10.1002/humu.21441 · Cited by 23 · cited 1×
“To assess co-segregation in multiple affected family members, the simplified method of segregation analysis (SISA) was applied [22,23] and classified according to recent recommendations to define co-segregation to fit the guidelines of the American College of Medical Genetics and Genomics and the Association for Molec…”
MethodA novel ferroportin mutation in a Canadian family with autosomal dominant hemochromatosis
Morris, T. J., Litvinova, M. M., Ralston, D., Mattman, A., Holmes, D. T., & Lockitch, G. (2005) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2005.07.007 · Cited by 23 · cited 3×
“7 Arg88Gly IC/PM ↓ yes --7 3 3 [8,11,82] Leu129Pro PM ↓ yes ↓yes -5 3 2 [83] Arg178Gln PM ↓ yes --26 17 [75,82,84,85] Asn185Asp PM ↓ yes --19 4 6 [9,11,86] Sum: 4 LOF Hepcidin Sensitive 57 27 11 Ala77Asp IC/PM ↓ conflicting not reliable@ no uptake 26 15 11 [1,2,8,11,34,35,39,41,42,56,57,66,71,73,87–90] Gly80Ser ↓PM ↓&…”
Lee, P. L., Gelbart, T., West, C., & Barton, J. C. (2007) · Acta Haematologica · doi:10.1159/000112830 · Cited by 22
McDonald, C. J., Ostini, L., Bennett, N. J., Subramaniam, N., Hooper, J. D., Velasco, G., Wallace, D. F., & Subramaniam, V. N. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00264.2014 · Cited by 22
Wallace, D. F., McDonald, C. J., Ostini, L., Iser, D., Tuckfield, A., & Subramaniam, V. N. (2017) · American Journal of Hematology · doi:10.1002/ajh.24844 · Cited by 21 · cited 1×
“Sum: 13 GOF Uncertain/Conflicting/Unknown 61 32 27 Asp84Glu – ↓ no – – 1 [43] Val162del IC/↓PM ↓ no no ↓↓uptake 50 39 2 [6,8,35,43,51,55,56,66–79] Asp181Asn PM ↓ no no – 6 6 [51] Asp181Val ↓PM ↓ no no – 10 10 [8,42,46,80] Gly490Asp IC/PM ↓ no no no uptake 12 9 3 [8,34,55,81]”
McDonald, C. J., Wallace, D. F., Ostini, L., Bell, S., Demediuk, B., & Subramaniam, V. N. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.07.048 · Cited by 20 · cited 6×
“Ala77Asp IC/PM ↓ conflicting not reliable@ no uptake 26 15 11 [1,2,8,11,34,35,39,41,42,56,57, 66,71,73,87–90] Gly80Ser ↓PM ↓& not reliable@ not reliable@ normal uptake& 24 15 3 [8,57,73,87,88,91,92] Ile152Phe PM ↓ ↓ ↓ – 2 [39,93] Asp157Gly IC/PM ↓ conflicting no& – 4 3 1 [8,34,55,56,61] Asp157Tyr ↓PM ↓ – – – 2 1 1 [8,…”
BackgroundMethodInfluentialIron overload patients with unknown etiology from national survey in Japan
Ikuta, K., Hatayama, M., Addo, L., Toki, Y., Sasaki, K., Tatsumi, Y., Hattori, A., Kato, A., Kato, K., Hayashi, H., et al. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2141-9 · Cited by 20
Does the SLC40A1 gene modify HFE-related haemochromatosis phenotypes?
Altés, A., Bach, V., Ruiz, A., Esteve, A., Remacha, A. F., Sardà, M. P., Félez, J., & Baiget, M. (2008) · Annals of Hematology · doi:10.1007/s00277-008-0590-9 · Cited by 18 · cited 1×
“Cys282Tyr variants in the HFE molecule [13].”
A novel mutation in the SLC40A1 gene associated with reduced iron export in vitro
Moreno‐Carralero, M., Muñoz‐Muñoz, J., Cuadrado‐Grande, N., López‐Rodríguez, R., Hernández‐Alfaro, M. J., del‐Castillo‐Rueda, A., de Salamanca, R. E., Méndez, M., & Morán‐Jiménez, M. (2014) · American Journal of Hematology · doi:10.1002/ajh.23714 · Cited by 17
Chen, S. ‐., Yang, L. ‐., Chong, Y., Jie, Y., Wu, Y., Yang, J., Lin, G., & Li, X. (2015) · Internal Medicine Journal · doi:10.1111/imj.12764 · Cited by 16
An, P., Jiang, L., Guan, Y., Wang, H., Wang, J., Tian, Y., Yang, W., Shi, Y., Xue, J., Min, J., et al. (2017) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.01.002 · Cited by 16 · cited 4×
“Sum: 7 GOF Hepcidin Sensitive: Neutral 12 7 3 Ala69Thr PM = – ↓! – 4 2 2 [42,51,52] Val72Phe PM = yes ↓! ↓binding 5 2 3 [30,53] Asn144Asp PM =# conflicting no# ↓binding/uptake 2 1 [30–32,35,54] Asn144His PM = conflicting yes ↓uptake 20 13 7 [3,6,31,34,35,39,40,42,55–59] Asn144Thr PM = conflicting yes# ↓uptake 1 1 [6,3…”
InfluentialPhenotypic expression of ferroportin disease in a family with the N144H mutation
Rosmorduc, O., Wendum, D., Arrivé, L., ElNaggar, A. C., Ennibi, K., Hannoun, L., Charlotte, F., Grangé, J., & Poupon, R. Y. (2008) · Gastroentérologie Clinique et Biologique · doi:10.1016/j.gcb.2008.01.030 · Cited by 15 · cited 1×
“In three additional patients, the administration of erythropoietin resulted in an increase of Hb and continuation of the phlebotomy regimen [59,107].”
BackgroundIron chelation with deferasirox in a patient with de-novo ferroportin mutation
Ünal, Ş., Piperno, A., & Gümrük, F. (2015) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2015.01.002 · Cited by 15 · cited 1×
“Treatment with deferasirox resulted in a dramatic decrease in serum ferritin concentration in two patients, but was not successful in another [52,76,96].”
BackgroundSaja, K., Bignell, P. A., Robson, K., & Provan, D. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08137.x · Cited by 13
Yamashita, T., Morotomi, N., Sohda, T., Hayashi, H., Yoshida, N., Ochi, K., Ohkura, I., Karita, M., Fujiwara, H., Yamashita, H., et al. (2014) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-014-0487-1 · Cited by 13
Two novel mutations in the SLC40A1 and HFE genes implicated in iron overload in a Spanish man
Rueda, A. D. C., Moreno‐Carralero, M., Álvarez-Sala, J. L., Cuadrado‐Grande, N., de Salamanca, R. E., Méndez, M., & Morán‐Jiménez, M. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01565.x · Cited by 13
Albuquerque, D., Manco, L., Loua, K. M., Arez, A. P., Trovoada, M. J., Relvas, L., Millimono, T. S., Rath, S. L., Lopes, D., Nogueira, F., et al. (2011) · Annals of Human Biology · doi:10.3109/03014460.2010.541496 · Cited by 13
Yamakawa, N., Oe, K., Yukawa, N., Murakami, K., Nakashima, R., Imura, Y., Yoshifuji, H., Ohmura, K., Miura, Y., Tomosugi, N., et al. (2016) · Internal Medicine · doi:10.2169/internalmedicine.55.6565 · Cited by 13 · cited 1×
“Cys326Tyr PM = no no ↓/no uptake 4 4 [8,31,34,35,39–44] Tyr333His PM = no no 5 5 [45] Tyr501Cys PM = no no ↓binding 7 2 5 [30,33,46] Asp504Asn PM = no no ↓binding/uptake 2 2 [8,30] His507Arg PM = no no ↓↓ubiquitination 4 4 [30,41,47]”
Multi-Organ Iron Overload in an African-American Man with ALAS2 R452S and SLC40A1 R561G
Sussman, N., Lee, P. L., Dries, A. M., Schwartz, M. R., & Barton, J. C. (2008) · Acta Haematologica · doi:10.1159/000181183 · Cited by 12 · cited 2×
“One patient with a GOF mutation died of multiorgan failure due to widespread iron deposition [50].”
BackgroundLim, F., Dooley, J. S., Roques, A. W. W., Grellier, L., Dhillon, A. P., & Walker, A. P. (2007) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2007.11.001 · Cited by 12 · cited 1×
“In contrast to the current consensus [1,2,4,6,8,40,71,83,92,105], patients with LOF variants were not less tolerant to phlebotomy than patients with GOF variants (Table 3).”
ResultMild Iron Overload in an African American Man with SLC40A1 D270V
Lee, P. L., Gaasterland, T., & Barton, J. C. (2012) · Acta Haematologica · doi:10.1159/000337034 · Cited by 11
G80S-linked ferroportin disease: The first clinical description in a Greek family
Mougiou, A., Pietrangelo, A., Caleffi, A., Kourakli, A., Καρακάντζα, Μ., & Zoumbos, N. C. (2008) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2008.03.002 · Cited by 10 · cited 3×
“7 Arg88Gly IC/PM ↓ yes --7 3 3 [8,11,82] Leu129Pro PM ↓ yes ↓yes -5 3 2 [83] Arg178Gln PM ↓ yes --26 17 [75,82,84,85] Asn185Asp PM ↓ yes --19 4 6 [9,11,86] Sum: 4 LOF Hepcidin Sensitive 57 27 11 Ala77Asp IC/PM ↓ conflicting not reliable@ no uptake 26 15 11 [1,2,8,11,34,35,39,41,42,56,57,66,71,73,87–90] Gly80Ser ↓PM ↓&…”
Majore, S., di Patti, M. C. B., Valiante, M., Polticelli, F., Cortese, A., Bartolomeo, S. D., Bernardo, C. D., Muro, M. D., Faienza, F., Radio, F. C., et al. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.11.006 · Cited by 10 · cited 9×
“Sum: 13 GOF Uncertain/Conflicting/Unknown 61 32 27 Asp84Glu – ↓ no – – 1 [43] Val162del IC/↓PM ↓ no no ↓↓uptake 50 39 2 [6,8,35,43,51,55,56,66–79] Asp181Asn PM ↓ no no – 6 6 [51] Asp181Val ↓PM ↓ no no – 10 10 [8,42,46,80] Gly490Asp IC/PM ↓ no no no uptake 12 9 3 [8,34,55,81]”
BackgroundInfluentialNovel human pathological mutations. Gene symbol: FBN1. Disease: Marfan syndrome.
Relvas, L., Claro, M. T., Bento, M. C., & Ribeiro, M. L. (2009) · PubMed · Cited by 9
Duca, L., Delbini, P., Nava, I., Vaja, V., Fiorelli, G., & Cappellini, M. D. (2009) · American Journal of Hematology · doi:10.1002/ajh.21465 · Cited by 8
Ferroportin mutations: a tale of two phenotypes
Nemeth, E. (2005) · Blood · doi:10.1182/blood-2005-02-0771 · Cited by 8 · cited 1×
“In contrast to the current consensus [1,2,4,6,8,40,71,83,92,105], patients with LOF variants were not less tolerant to phlebotomy than patients with GOF variants (Table 3).”
ResultTertre, M. L., Ka, C., Guellec, J., Gourlaouen, I., Férec, C., Callebaut, I., & Gac, G. L. (2017) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2017.07.002 · Cited by 8
Loss-of-function ferroportin disease: novel mechanistic insights and unanswered questions
Vlasveld, L. T., & Swinkels, D. W. (2018) · Haematologica · doi:10.3324/haematol.2018.203315 · Cited by 8 · cited 1×
“Taken together, these experimental data suggest a regulation difference of ferroportin production and activation, between enterocytes and macrophages [153].”
BackgroundSelf-citationHayashi, H., Yano, M., Urawa, N., Mizutani, A., Hamaoka, S., Araki, J., Kojima, Y., Naito, Y., Kato, A., Tatsumi, Y., et al. (2018) · Internal Medicine · doi:10.2169/internalmedicine.0481-17 · Cited by 7 · cited 5×
“Pharmaceuticals 2019, 12, 132 10 of 29 HIC, hepatic iron content; ALT, alanine aminotransferase.”
BackgroundInfluentialGalicia‐Poblet, G., Cid‐París, E., López‐Andrés, N., Losada‐Pajares, A., Jurado-López, J. C., Moreno‐Carralero, M., & Morán‐Jiménez, M. (2014) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000648 · Cited by 6
Wolff, F., Bailly, B., Gulbis, B., & COTTON, F. J. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.12.024 · Cited by 6 · cited 4×
“In contrast to the current consensus [1,2,4,6,8,40,71,83,92,105], patients with LOF variants were not less tolerant to phlebotomy than patients with GOF variants (Table 3).”
ResultInfluentialFerroportin-related haemochromatosis associated with novel Y64H mutation of the SCL40A1 gene
Raszeja‐Wyszomirska, J., Caleffi, A., Milkiewicz, P., & Pietrangelo, A. (2014) · Gastroenterology Review · doi:10.5114/pg.2014.46167 · Cited by 6 · cited 3×
“7 Arg88Gly IC/PM ↓ yes --7 3 3 [8,11,82] Leu129Pro PM ↓ yes ↓yes -5 3 2 [83] Arg178Gln PM ↓ yes --26 17 [75,82,84,85] Asn185Asp PM ↓ yes --19 4 6 [9,11,86] Sum: 4 LOF Hepcidin Sensitive 57 27 11 Ala77Asp IC/PM ↓ conflicting not reliable@ no uptake 26 15 11 [1,2,8,11,34,35,39,41,42,56,57,66,71,73,87–90] Gly80Ser ↓PM ↓&…”
Detection of a rare mutation in the ferroportin gene through targeted next generation sequencing.
Ferbo, L., Manzini, P. M., Badar, S., Campostrini, N., Ferrarini, A., Delledonne, M., Francisci, T., Tassi, V., Valfrè, A., Dall'Omo, A. M., et al. (2016) · PubMed · doi:10.2450/2016.0286-15 · Cited by 6 · cited 2×
“Sum: 7 GOF Hepcidin Sensitive: Neutral 12 7 3 Ala69Thr PM = – ↓! – 4 2 2 [42,51,52] Val72Phe PM = yes ↓! ↓binding 5 2 3 [30,53] Asn144Asp PM =# conflicting no# ↓binding/uptake 2 1 [30–32,35,54] Asn144His PM = conflicting yes ↓uptake 20 13 7 [3,6,31,34,35,39,40,42,55–59] Asn144Thr PM = conflicting yes# ↓uptake 1 1 [6,3…”
BackgroundMuehlenberg, K., Faltermeier, N., Lohse, P., Tannapfel, A., & Pech, O. (2014) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0034-1366809 · Cited by 4 · cited 1×
“Treatment with deferasirox resulted in a dramatic decrease in serum ferritin concentration in two patients, but was not successful in another [52,76,96].”
BackgroundLogie, C. (2012) · InTech eBooks · doi:10.5772/2153 · Cited by 2
Point Mutations in Ferroportin Disease: Genotype/Phenotype Correlation
Akoum, R. (2012) · InTech eBooks · doi:10.5772/34218 · Cited by 1
Speletas, M. G., Kioumi, A., & Germenis, A. E. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.03.005 · Cited by 1 · cited 3×
“7 Arg88Gly IC/PM ↓ yes --7 3 3 [8,11,82] Leu129Pro PM ↓ yes ↓yes -5 3 2 [83] Arg178Gln PM ↓ yes --26 17 [75,82,84,85] Asn185Asp PM ↓ yes --19 4 6 [9,11,86] Sum: 4 LOF Hepcidin Sensitive 57 27 11 Ala77Asp IC/PM ↓ conflicting not reliable@ no uptake 26 15 11 [1,2,8,11,34,35,39,41,42,56,57,66,71,73,87–90] Gly80Ser ↓PM ↓&…”
Research works printed but not linked: 4
- 2015, A Pediatric Case Report of Ferroportin Disease, J. Pediatr. Gastroenterol. Nutr., 63, e205
- Relvas, 2009, Novel human pathological mutation: Gene Symbol: SLC40A1; Disease: Haemochromatosis, type IV, Hum. Genet., 125, 338
- Muehlenberg, 2014, [Family with marked hyperferritinemia as a result of hemochromatosis type 4 (ferroportin disease)], Z. Gastroenterol., 52, 1075
- Caetano, G., Relvas, L., Bento, C., Silveira, M.P., and Ribeiro, L. (2009, January 7–11). Atypical iron deficiency anemia—Association of two new mutations in ferroportin and TMPRSS6 genes. Proceedings of the International BioIron Society Annual Meeting, Porto, Portugal.
Cited by
Structures and General Transport Mechanisms by the Major Facilitator Superfamily (MFS)
Drew, D., North, R. A., Nagarathinam, K., & Tanabe, M. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00983 · Cited by 465
Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms
Billesbølle, C. B., Azumaya, C. M., Kretsch, R. C., Powers, A. S., Gonen, S., Schneider, S., Arvedson, T., Dror, R. O., Cheng, Y., & Manglik, A. (2020) · Nature · doi:10.1038/s41586-020-2668-z · Cited by 344
Hemochromatosis classification: update and recommendations by the BIOIRON Society
Girelli, D., Busti, F., Brissot, P., Cabantchik, I., Muckenthaler, M. U., & Porto, G. (2022) · Blood · doi:10.1182/blood.2021011338 · Cited by 187
Structural basis of ion transport and inhibition in ferroportin
Pan, Y., Ren, Z., Gao, S., Shen, J., Wang, L., Xu, Z., Yu, Y., Bachina, P., Zhang, H., Fan, X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19458-6 · Cited by 81
Interplay of oxidative stress and antioxidant mechanisms in cancer development and progression
Jomová, K., Alomar, S. Y., Valko, R., Fresser, L., Nepovimová, E., Kuča, K., & Valko, M. (2025) · Archives of Toxicology · doi:10.1007/s00204-025-04146-5 · Cited by 130
“Ferroportin is a transmembrane protein that transports iron from the intracellular space to the extracellular environment via the iron chaperone poly (RC)-binding protein 2 (PCBP2), which has been found to have ambiguous functions in a variety of cancers (Vlasveld et al. 2019).”
Metadata
- Authors
- Vlasveld, L. T., Janssen, R., Bardou-Jacquet, E., Venselaar, H., Hamdi-Roze, H., Drakesmith, H., & Swinkels, D. W.
- Affiliations
- Bronovo Hospital (NL)
- Radboud University Medical Center (NL)
- Liver Diseases Department, French Reference Centre for Rare Iron Overload Diseases of Genetic Origin, University Hospital Pontchaillou, 35033 Rennes, France
- Molecular Genetics Department, French Reference Centre for Rare Iron Overload Diseases of Genetic Origin, University Hospital Pontchaillou, 35033 Rennes, France
- University of Oxford (GB)
- Corresponding author
- Swinkels, Dorine W.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2019-09-09
- Volume
- 12
- Issue
- 3
- Pages
- 132
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC6789780
- OpenAlex
- W2972637634
- Cited by
- 57
- References
- 150
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 9 · 2023: 9 · 2022: 1 · 2021: 14 · 2020: 9 · 2019: 2
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- Medical Research Council (MC_UU_00008/10)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- ferroportin disease, iron overload, hereditary hemochromatosis, loss-of-function mutations, gain-of-function mutations, transferrin saturation, variant pathogenicity, functional assays, in silico prediction models, patient registry
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.